TissGeneSummary for RNF133 |
Gene summary |
Basic gene information | Gene symbol | RNF133 |
Gene name | ring finger protein 133 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 7q31.32 | |
Type of gene | protein-coding | |
RefGenes | NM_139175.1, | |
Description | E3 ubiquitin-protein ligase RNF133 | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
Ensembl : ENSG00000188050 | ||
HPRD : 11505 | ||
Vega : OTTHUMG00000157092 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_RNF133 | |
BioGPS: 168433 | ||
Pathway | NCI Pathway Interaction Database: RNF133 | |
KEGG: RNF133 | ||
REACTOME: RNF133 | ||
Pathway Commons: RNF133 | ||
Context | iHOP: RNF133 | |
ligand binding site mutation search in PubMed: RNF133 | ||
UCL Cancer Institute: RNF133 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of RNF133 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for RNF133 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
LUSC | -1.799852433 | -0.290279884 | -1.509572549 | 5.74E-20 | 6.77E-19 |
KIRP | -1.812013585 | -0.70297921 | -1.109034375 | 2.32E-11 | 2.99E-10 |
Top |
TissGene-miRNA for RNF133 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for RNF133 |
TissGeneSNV for RNF133 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.R270C | SKCM | 4 |
p.Y41F | LUAD | 1 |
p.L104R | GBM | 1 |
p.F164I | SKCM | 1 |
p.R70I | HNSC | 1 |
p.H51Y | LIHC | 1 |
p.G134V | HNSC | 1 |
p.L301P | DLBC | 1 |
p.T161M | LUAD | 1 |
p.D149N | LUSC | 1 |
p.W286C | LUAD | 1 |
p.L239R | DLBC | 1 |
p.R262C | PAAD | 1 |
p.G57R | STAD | 1 |
p.A175V | SKCM | 1 |
p.G123A | LUAD | 1 |
p.E353K | BLCA | 1 |
p.K264T | SKCM | 1 |
p.F62L | PAAD | 1 |
p.I184V | HNSC | 1 |
p.E162D | UCEC | 1 |
p.P265S | SKCM | 1 |
p.R240Q | COAD | 1 |
p.F143C | HNSC | 1 |
p.E79Q | BLCA | 1 |
p.T198I | LUAD | 1 |
p.H47Y | LUAD | 1 |
p.H279Q | LUAD | 1 |
p.H144N | UCEC | 1 |
p.S125N | STAD | 1 |
p.T120A | LUAD | 1 |
p.E248K | CESC | 1 |
p.N84S | STAD | 1 |
p.I167L | GBM | 1 |
p.E248* | SKCM | 1 |
p.H47Y | HNSC | 1 |
p.R262H | STAD | 1 |
p.R94Q | DLBC | 1 |
p.T292A | PRAD | 1 |
p.G134A | LUSC | 1 |
p.R217S | LGG | 1 |
p.I91V | UCEC | 1 |
p.G123R | SKCM | 1 |
p.R240X | SKCM | 1 |
p.M187I | CESC | 1 |
p.S98L | LUAD | 1 |
p.L320I | COAD | 1 |
p.Q231R | HNSC | 1 |
p.I210V | LUAD | 1 |
p.F164S | SKCM | 1 |
p.E121D | LUAD | 1 |
p.K159* | LUSC | 1 |
p.V139G | THYM | 1 |
p.R262C | KIRP | 1 |
p.R270H | UCEC | 1 |
p.R107P | LUAD | 1 |
p.I185M | LGG | 1 |
p.P374L | SKCM | 1 |
p.Y130C | SKCM | 1 |
p.S65N | CESC | 1 |
p.R222K | SKCM | 1 |
Top |
TissGeneCNV for RNF133 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for RNF133 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for RNF133 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for RNF133 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for RNF133 |
TissGeneDrug for RNF133 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for RNF133 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0040336 | Tobacco Use Disorder | 1 | GAD |